Prime Medicine, Inc.PRMENASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P5
Near historical low
vs 3Y Ago
-1.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -21.10% |
| Q3 2025 | 6.32% |
| Q2 2025 | 2.00% |
| Q1 2025 | 18.94% |
| Q4 2024 | -15.46% |
| Q3 2024 | -6.34% |
| Q2 2024 | 14.02% |
| Q1 2024 | -8.89% |
| Q4 2023 | 1.20% |
| Q3 2023 | 18.41% |
| Q2 2023 | 12.04% |
| Q1 2023 | 6.26% |
| Q4 2022 | 16.03% |
| Q3 2022 | 32.24% |
| Q2 2022 | 38.48% |
| Q1 2022 | -74.14% |
| Q4 2021 | 614.72% |
| Q3 2021 | 29.94% |
| Q2 2021 | 24.73% |
| Q1 2021 | 262.67% |
| Q4 2020 | 0.00% |
| Q4 2019 | 0.00% |